Cargando…
Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
BACKGROUND/HISTORICAL PERSPECTIVE: Availability of biologic disease-modifying antirheumatic drugs (bDMARDs) has improved clinical outcomes in rheumatoid arthritis, but it also increased the cost of treatment. Biosimilars, the regulated copies of biologic products, have a potential to reduce health c...
Autores principales: | Azevedo, Valderilio Feijó, Babini, Alejandra, Caballero-Uribe, Carlo V., Castañeda-Hernández, Gilberto, Borlenghi, Cecilia, Jones, Heather E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392209/ https://www.ncbi.nlm.nih.gov/pubmed/30059414 http://dx.doi.org/10.1097/RHU.0000000000000881 |
Ejemplares similares
-
Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view
por: Pineda, Carlos, et al.
Publicado: (2015) -
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021) -
The biosimilars journey: current status and ongoing challenges
por: Kos, Igor Age, et al.
Publicado: (2018) -
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
por: Scheinberg, Morton, et al.
Publicado: (2018) -
Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists
por: Urbano, Paulo César Martins, et al.
Publicado: (2014)